Therapeutic Area

Breast Cancer

Therapeutic area intelligence for Breast Cancer with 15 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 15
Catalysts: 0
Companies: 4

Companies

Assets

Recent signals(15)

ClinicalJune 21, 2026

Study on Gut Microbiota and Cachexia in Breast Cancer Patients Under Home Care

A study is evaluating the association between cancer cachexia and gut microbiota in breast cancer patients receiving home care, including the impact of a probiotic mixture.

ClinicalJune 21, 2026

Targeting Macrophage Cytokine Circuit Offers New Strategy Against TNBC Metastasis

Tumor-educated macrophages promote TNBC metastasis through a cytokine circuit, which can be disrupted pharmacologically.

ClinicalJune 20, 2026

Trial on Mobile Health Platform to Improve Adherence in Metastatic Breast Cancer Patients

A clinical trial is assessing the effectiveness of the CONCURxP platform in improving medication adherence among metastatic breast cancer patients on CDK4/6 inhibitors.

ClinicalJune 18, 2026

Study on De-escalation of Radiation Therapy in Node Negative Breast Cancer

A clinical trial is investigating the de-escalation of radiation therapy in women with clinically node negative breast cancer undergoing lumpectomy.

ClinicalJune 18, 2026

Study on Educational Intervention for Breast Cancer Patients' Adherence and Sexual Function

This study evaluates the impact of an educational intervention on sexual function and treatment adherence in women with breast cancer.

ClinicalJune 17, 2026

Study on Early Rehabilitation Protocol for Breast Cancer Surgery Shows Promising Safety and Feasibility

A new early rehabilitation protocol, EMOVE-BCS-LaFe, is being evaluated for safety and feasibility in breast cancer surgery patients.

ClinicalJune 17, 2026

STARD10's Role in HER2+ Breast Cancer Progression and Lipid Metabolism

STARD10 is implicated in the progression of HER2+ breast cancer and regulates intracellular lipid metabolism via the cAMP/PKA/CREB1 signaling pathway.

ClinicalJune 17, 2026

DB-1303/BNT323 Trial in HER2-Low Metastatic Breast Cancer Initiated

A clinical trial is underway to evaluate DB-1303/BNT323 against investigator's choice chemotherapy in HER2-low, HR+ metastatic breast cancer.

ClinicalJune 17, 2026

Phase III Trial of Giredestrant vs Endocrine Therapy in ER+ HER2- Early Breast Cancer

A Phase III trial is underway to evaluate giredestrant against standard endocrine therapy in ER-positive, HER2-negative early breast cancer.

ClinicalJune 17, 2026

Phase III Trial Evaluates Hormone Therapy and Chemotherapy in Invasive Breast Cancer

A randomized phase III trial is assessing the efficacy of tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy in invasive breast cancer.

RegulatoryJune 16, 2026

FDA ODAC Vote Against Camizestrant for HR-Positive Breast Cancer Raises Concerns

The FDA's ODAC did not reach a majority vote in favor of camizestrant's benefit-risk profile for advanced HR-positive breast cancer.

ClinicalJune 16, 2026

Roche to Present Promising Giredestrant Data at ASCO 2026 for Early Breast Cancer

Roche will present new data from the lidERA and persevERA studies, indicating giredestrant's potential as a new standard of care in early and advanced ER-positive breast cancer.

ClinicalJune 16, 2026

Roche to Present Promising Giredestrant Data at ASCO 2026 for Early Breast Cancer

Roche will present new data from the lidERA and persevERA studies, highlighting giredestrant's potential as a new standard of care for ER-positive breast cancer.

RegulatoryJune 16, 2026

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer

The FDA has accepted Roche's NDA for giredestrant, an oral SERD, under priority review based on phase III data showing a 30% reduction in invasive disease recurrence or death compared to standard therapy.

RegulatoryJune 16, 2026

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer

The FDA has accepted Roche's NDA for giredestrant, showing a 30% reduction in invasive disease recurrence compared to standard therapy.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Breast Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.